Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of…
AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of…